Gergel Ivan P.
SEC-identified person · CIK 1328288 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Neurotrope, Inc. NTRP | Director | filed 2018 - 2020 |
| Corium International, Inc. CORI | Director | filed 2014 - 2018 |
| Nektar Therapeutics NKTR | SVP Drug Development & CMO | filed 2014 - 2017 |
| Endo International plc ENDP | EVP, R&D and CSO | filed 2014 - 2014 |
| Endo Pharmaceuticals Holdings INC ENDP | EVP, Research & Development | filed 2008 - 2014 |
| Indevus Pharmaceuticals INC IDEV | Director | filed 2009 - 2009 |
| Forest Laboratories, LLC frx | Sr VP - Chief Sci. Officer | filed 2006 - 2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.